title: Management of patients with adrenal cancer: recommendations of an international consensus conference.
abstract: Adrenocortical carcinomas are rare, highly malignant tumors that account for only 0.2% of deaths due to cancer. Given the limited number of patients seen in most medical centers with this diagnosis, series usually reported are small and clinical trials not randomized or blinded. In an attempt to answer important questions concerning the management of patients with adrenal cancer, a consensus conference was organized and held at the University of Michigan in Ann Arbor, MI, 11-13 September 2003, with the participation of an international group of physicians who had reported on the largest series of patients with this disease and who had recognized basic and clinical research expertise in adrenal cortical cancer. Totally 43 questions were addressed by the presenters and recommendations discussed in plenary and breakout sessions. Evidence for the recommendations of this conference was at the 2-4+ level and based on available literature and participants' experience. In addition to setting up guidelines in specific areas of the diagnosis and treatment of adrenal cancer, the conference recommended and initiated the planning of an international prospective trial for treatment of patients with adrenal cancer in stages III and IV. In terms of new therapies, first trials of dendritic cell therapy in human subjects with adrenal cancer have been started, but it is too early to comment on efficacy. Different strategies of immunotherapy, including DNA vaccination are currently being tried in animal models. There are no clinical gene therapy trials for human adrenal cortical cancer. The adrenals are a preferred target for adenovirus and the results of gene therapy in preclinical studies are promising. In addition, there is evidence that histone deacetylase inhibitors can further enhance the rate of adenoviral infectivity in human adrenal cancer cells. Testing of retroviral vectors, non-viral vectors, small interfering RNA technology, and combined approaches could be performed in various laboratories. Anti-angiogenic substances have only been applied in preclinical studies. The use of these and other agents in the treatment of adrenal cancer should be hypothesis-driven and based on a thorough analysis of tumor biology.
authors.affiliation: Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, USA. dschtein@umich.edu
authors.forename: D E
authors.initials: DE
authors.lastname: Schteingart
authors.forename: G M
authors.initials: GM
authors.lastname: Doherty
authors.forename: P G
authors.initials: PG
authors.lastname: Gauger
authors.forename: T J
authors.initials: TJ
authors.lastname: Giordano
authors.forename: G D
authors.initials: GD
authors.lastname: Hammer
authors.forename: M
authors.initials: M
authors.lastname: Korobkin
authors.forename: F P
authors.initials: FP
authors.lastname: Worden
mesh_terms: D000310:Adrenal Gland Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D006801:Humans; D009367:Neoplasm Staging